ESSA Pharma Inc.

Two and a half months after its first US Food and Drug Administration approval for Incyte Corp.-partnered Niktimvo (axatilimab-csfr) in chronic graft-versus-host disease (GVHD), Syndax Pharmaceuticals

DRI Healthcare Trust launched an initial public offering in Canada, grossing $400m from the IPO and a concurrent private placement, to fund its operations, purchase royalties from a portfolio of 18 ph

Investor interest in initial public offerings in the US by biopharmaceutical companies apparently has not abated in the new year, with two oncology-focused firms – Cullinan Management Inc. and Gracel